Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Cash & Current Investments data on file, last reported at $413.0 million in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $413.0 million, down 16.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $413.0 million (down 16.46% YoY), and the FY2025 annual result was $680.0 million, up 11.48% from the prior year.
• Cash & Current Investments declined to $413.0 million in Q1 2026 per RARE's latest filing, from $680.0 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $888.7 million in Q3 2022 and troughed at $412.1 million in Q1 2024.
• A 5-year average of $581.5 million and a median of $577.6 million in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments plunged 50.25% in 2023, then surged 40.61% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $747.8 million in 2022, then declined by 22.75% to $577.6 million in 2023, then increased by 5.6% to $610.0 million in 2024, then increased by 11.48% to $680.0 million in 2025, then slumped by 39.26% to $413.0 million in 2026.
• Business Quant data shows RARE's Cash & Current Investments at $413.0 million in Q1 2026, $680.0 million in Q4 2025, and $425.2 million in Q3 2025.